KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) Net Margin (2017 - 2025)

Moderna (MRNA) has disclosed Net Margin for 9 consecutive years, with 121.83% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin fell 2594.0% to 121.83% in Q4 2025 year-over-year; TTM through Dec 2025 was 145.16%, a 3959.0% decrease, with the full-year FY2025 number at 145.16%, down 3512.0% from a year prior.
  • Net Margin was 121.83% for Q4 2025 at Moderna, down from 19.69% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 67.51% in Q4 2021 to a low of 899.07% in Q1 2025.
  • A 5-year average of 165.33% and a median of 2.47% in 2024 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: soared 161304bps in 2021, then crashed -70784bps in 2024.
  • Moderna's Net Margin stood at 67.51% in 2021, then plummeted by -57bps to 28.82% in 2022, then tumbled by -73bps to 7.72% in 2023, then plummeted by -1342bps to 95.89% in 2024, then fell by -27bps to 121.83% in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Net Margin are 121.83% (Q4 2025), 19.69% (Q3 2025), and 580.99% (Q2 2025).